Lung cancer
Conditions
Interventions
Standard chemotherapy group:None
The sequential CDK4/6 inhibitor group after chemotherapy:None
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 to 75 years old, gender not limited; 2.Histopathologically or cytologically confirmed non-small cell lung cancer, including lung adenocarcinoma, lung squamous cell carcinoma, or other types of non-small cell lung cancer. 3.Clinical stage is locally advanced unresectable, recurrent, or metastatic non-small cell lung cancer. 4.Previously received at least 2 cycles of standard chemotherapy, including platinum-based doublet chemotherapy or clinically commonly used single-agent/combination chemotherapy regimens. 5.At least one set of imaging data available for efficacy evaluation before or during treatment. 6.Accessible tumor tissue paraffin blocks or unstained slides available for immunohistochemical detection of RB, pRB, p16, Cyclin D1, CDK4, CDK6, Ki-67, etc., or prior next-generation sequencing data available for RB1 and related pathway analysis. 7.Relatively complete clinical data, including age, sex, smoking history, ECOG score, pathological type, TNM stage, driver gene status, number of treatment lines, chemotherapy regimen, adverse reactions, efficacy evaluation, and follow-up outcomes.
Exclusion criteria
Exclusion criteria: 1.Pathological type is small cell lung cancer, pulmonary neuroendocrine carcinoma, or mixed lung cancer containing small cell lung cancer components. 2.Severe lack of clinical data, making it impossible to determine treatment plan, efficacy, or survival outcomes. 3.Insufficient imaging data to evaluate efficacy according to RECIST 1.1 criteria. 4.Poor quality of pathological tissue, unable to complete RB1 phenotype-related testing. 5.Concurrent other malignant tumors and inability to determine whether survival outcomes are primarily determined by non-small cell lung cancer. 6.The investigator determines that it is unsuitable for inclusion in the analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Progression free survival;Overall survival;Duration of relief; | — |
Countries
China
Contacts
Public ContactXiao Hui
Shanghai General Hospital
Outcome results
None listed